- Home
- EONR vs RNAZ Comparison
EONR vs RNAZ Comparison
Compare EONR & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EONR
- RNAZ
- Stock Information
- Founded
- EONR 2020
- RNAZ 2016
- Country
- EONR United States
- RNAZ United States
- Employees
- EONR N/A
- RNAZ N/A
- Industry
- EONR
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- EONR
- RNAZ Health Care
- Exchange
- EONR NYSE
- RNAZ Nasdaq
- Market Cap
- EONR 8.0M
- RNAZ 7.2M
- IPO Year
- EONR N/A
- RNAZ 2021
- Fundamental
- Price
- EONR $0.62
- RNAZ $8.08
- Analyst Decision
- EONR Strong Buy
- RNAZ Strong Buy
- Analyst Count
- EONR 1
- RNAZ 1
- Target Price
- EONR $4.50
- RNAZ $20.00
- AVG Volume (30 Days)
- EONR 1.3M
- RNAZ 4.3M
- Earning Date
- EONR 03-04-2025
- RNAZ 03-31-2025
- Dividend Yield
- EONR N/A
- RNAZ N/A
- EPS Growth
- EONR N/A
- RNAZ N/A
- EPS
- EONR N/A
- RNAZ N/A
- Revenue
- EONR $21,714,016.00
- RNAZ N/A
- Revenue This Year
- EONR N/A
- RNAZ N/A
- Revenue Next Year
- EONR $78.80
- RNAZ N/A
- P/E Ratio
- EONR N/A
- RNAZ N/A
- Revenue Growth
- EONR N/A
- RNAZ N/A
- 52 Week Low
- EONR $0.51
- RNAZ $2.66
- 52 Week High
- EONR $6.00
- RNAZ $66.33
- Technical
- Relative Strength Index (RSI)
- EONR N/A
- RNAZ 48.31
- Support Level
- EONR N/A
- RNAZ $10.02
- Resistance Level
- EONR N/A
- RNAZ $11.30
- Average True Range (ATR)
- EONR 0.00
- RNAZ 1.97
- MACD
- EONR 0.00
- RNAZ -0.18
- Stochastic Oscillator
- EONR 0.00
- RNAZ 26.75
About EONR EON RESOURCES INC
EON Resources Inc is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in the United States. Its current focus is as an upstream energy company producing oil and gas properties in the Permian Basin.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.